【摘要】：醫(yī)藥制造業(yè)是涉及國(guó)民健康、社會(huì)穩(wěn)定和經(jīng)濟(jì)發(fā)展的重要產(chǎn)業(yè)，也是世界上發(fā)展最快、競(jìng)爭(zhēng)最為激烈的產(chǎn)業(yè)之一。隨著經(jīng)濟(jì)開(kāi)放化進(jìn)程的加快，如何有效提升醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力，提高企業(yè)績(jī)效，保持企業(yè)持續(xù)發(fā)展，這無(wú)疑是當(dāng)今企業(yè)急需關(guān)注和解決的重要問(wèn)題。研究醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力與績(jī)效的關(guān)系，不僅對(duì)企業(yè)發(fā)展具有指導(dǎo)意義，而且對(duì)政府制定相關(guān)政策具有參考作用。 本文采用理論與實(shí)證相結(jié)合的分析方法，首先根據(jù)國(guó)內(nèi)外關(guān)于企業(yè)創(chuàng)新能力與績(jī)效的相關(guān)文獻(xiàn)及理論知識(shí)，界定了企業(yè)創(chuàng)新能力內(nèi)涵及醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力的構(gòu)成要素，闡述了醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力構(gòu)成要素即市場(chǎng)營(yíng)銷創(chuàng)新能力、管理創(chuàng)新能力、技術(shù)創(chuàng)新能力、制度創(chuàng)新能力這四要素的內(nèi)在關(guān)系及各要素對(duì)企業(yè)績(jī)效的作用機(jī)理；其次，基于醫(yī)藥制造業(yè)發(fā)展?fàn)顩r及行業(yè)特征，選取上交所36家醫(yī)藥制造業(yè)樣本企業(yè)，構(gòu)建了醫(yī)藥制造業(yè)上市公司創(chuàng)新能力評(píng)價(jià)指標(biāo)體系。并采用因子分析法分析得到醫(yī)藥制造業(yè)上市公司創(chuàng)新能力整體水平不高，企業(yè)之間創(chuàng)新能力差距較大，，應(yīng)加強(qiáng)創(chuàng)新能力的培育這一結(jié)論；再次，運(yùn)用主營(yíng)業(yè)務(wù)利潤(rùn)率來(lái)衡量企業(yè)績(jī)效，提出假設(shè)并建立回歸模型，得出醫(yī)藥制造業(yè)上市公司創(chuàng)新能力與企業(yè)績(jī)效呈正相關(guān)，企業(yè)創(chuàng)新能力四大要素對(duì)企業(yè)績(jī)效產(chǎn)生正面的影響。同時(shí)反映醫(yī)藥制造業(yè)上市公司創(chuàng)新能力的10大指標(biāo)中四大指標(biāo)（技術(shù)人員投入率、全員勞動(dòng)生產(chǎn)率、國(guó)有股占比、銷售人員投入率）與企業(yè)績(jī)效關(guān)系為負(fù)，表明醫(yī)藥制造業(yè)上市公司更應(yīng)注重這四個(gè)方面的投入；最后，依據(jù)理論及實(shí)證研究，對(duì)提升醫(yī)藥制造業(yè)企業(yè)創(chuàng)新能力提出了針對(duì)性的建議。
[Abstract]:Pharmaceutical manufacturing industry is an important industry involving national health, social stability and economic development. It is also one of the fastest growing and most competitive industries in the world. With the acceleration of the process of economic opening, how to effectively improve the innovation ability of pharmaceutical manufacturing enterprises, improve the performance of enterprises, and maintain the sustainable development of enterprises, this is undoubtedly an important issue that enterprises need to pay close attention to and solve. The study of the relationship between innovation ability and performance of pharmaceutical manufacturing enterprises is not only of guiding significance to the development of enterprises, but also of reference to the government in formulating relevant policies. This article uses the theory and the demonstration to combine the analysis method, first according to the domestic and foreign related literature and the theory knowledge about the enterprise innovation ability and the performance, has defined the enterprise innovation ability connotation and the medicine manufacturing enterprise innovation ability constituent factor. This paper expounds the internal relations of the four elements of pharmaceutical manufacturing enterprises' innovation ability, that is, marketing innovation ability, management innovation ability, technological innovation ability and institutional innovation ability, and the mechanism of each factor acting on the enterprise performance. Secondly, based on the development situation and industry characteristics of pharmaceutical manufacturing industry, 36 pharmaceutical manufacturing sample enterprises are selected from Shanghai Stock Exchange, and the evaluation index system of innovation ability of listed pharmaceutical manufacturing companies is constructed. The conclusion is that the overall level of innovation ability of listed pharmaceutical manufacturing companies is not high, and the gap between enterprises is large, so we should strengthen the cultivation of innovation ability. Thirdly, the main business profit margin is used to measure the performance of the company, and the hypothesis is put forward and the regression model is established. The conclusion is that the innovation ability of the listed pharmaceutical manufacturing company is positively correlated with the enterprise performance. The four elements of enterprise innovation ability have a positive effect on enterprise performance. At the same time, four of the 10 indexes reflecting the innovation ability of listed companies in pharmaceutical manufacturing industry (technical personnel input rate, total labor productivity, proportion of state-owned shares, investment rate of sales personnel) have negative relationship with enterprise performance. It shows that the listed companies in the pharmaceutical manufacturing industry should pay more attention to the investment in these four aspects; Finally, based on the theoretical and empirical research, some suggestions are put forward to improve the innovation ability of pharmaceutical manufacturing enterprises.
【學(xué)位授予單位】：重慶工商大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72;F273.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉玉來(lái);我國(guó)中小企業(yè)技術(shù)創(chuàng)新的制約因素及對(duì)策[J];北京大學(xué)學(xué)報(bào);2000年S1期

2 周亞虹;許玲麗;;民營(yíng)企業(yè)R&D投入對(duì)企業(yè)業(yè)績(jī)的影響——對(duì)浙江省桐鄉(xiāng)市民營(yíng)企業(yè)的實(shí)證研究[J];財(cái)經(jīng)研究;2007年07期

3 孫虹;;我國(guó)醫(yī)藥制造業(yè)技術(shù)創(chuàng)新相對(duì)效率研究[J];科技和產(chǎn)業(yè);2012年03期

4 陳廣宇;張國(guó)政;高麗萍;;基于AHP的企業(yè)創(chuàng)新能力相關(guān)因素分析[J];工業(yè)技術(shù)經(jīng)濟(jì);2009年10期

5 何建洪;賀昌政;;創(chuàng)新能力與創(chuàng)新型企業(yè)評(píng)價(jià)研究[J];管理學(xué)報(bào);2011年02期

6 陳紅川;;醫(yī)藥制造業(yè)技術(shù)創(chuàng)新能力評(píng)價(jià)實(shí)證研究[J];廣州大學(xué)學(xué)報(bào)(自然科學(xué)版);2013年04期

7 段福興,張建東,程鈞謨;企業(yè)知識(shí)創(chuàng)新能力模糊評(píng)價(jià)體系研究[J];華東經(jīng)濟(jì)管理;2005年05期

8 王穎;沈月春;;知識(shí)管理能力與技術(shù)創(chuàng)新能力對(duì)企業(yè)績(jī)效的協(xié)同影響[J];經(jīng)濟(jì)論壇;2008年03期

9 廖理,姜彥福;國(guó)有企業(yè)的技術(shù)創(chuàng)新、組織創(chuàng)新與制度創(chuàng)新[J];技術(shù)經(jīng)濟(jì);1996年09期

10 馬永紅;趙凌晨;劉拓;;創(chuàng)新型企業(yè)評(píng)價(jià)體系的構(gòu)建研究[J];技術(shù)經(jīng)濟(jì);2007年10期

相關(guān)博士學(xué)位論文 前2條

1 鄒鮮紅;我國(guó)醫(yī)藥制造業(yè)技術(shù)創(chuàng)新效率及其影響因素研究[D];中南大學(xué);2010年

2 白戈;營(yíng)銷能力與企業(yè)創(chuàng)新行為關(guān)系研究[D];西南財(cái)經(jīng)大學(xué);2010年

本文編號(hào)：2429804